Latest Biogen News & Updates

See the latest news and media coverage for Biogen. We track all announcements, press releases, and industry mentions in real time, all in one place.

Biogen

Biotechnology company for neurological, immune, and rare diseases

biogen.com

Headquarters: Cambridge, United States
Company type: Public company
Number of employees: 7,500–10,000
Industry: Pharmaceuticals

Last updated Today

Latest news about Biogen

In short: Biogen reported strong 2026 financial growth driven by new drug sales and its $5.6 billion Apellis acquisition despite trial setbacks.

Company announcements

July 29 Biogen

Biogen reports second quarter 2026 financial results

The company disclosed revenue and earnings for the quarter ended June 30, 2026.

July 14 Biogen

Biogen's LEQEMBI study shows 75.9% stable, 6.6% improved

The LEADER study presented at AAIC 2026 demonstrated that 82.5% of patients remained stable or improved, with consistent benefits across diverse populations.

July 14 Biogen

Biogen presents Phase 2 CELIA data for diranersen

The drug showed robust tau reduction and slowing of clinical decline in early Alzheimer's; 60mg dose had 42-50% slowing on cognitive endpoints.

July 13 Biogen

Biogen announces FDA approval of LEQEMBI IQLIK subcutaneous injection

The approval allows at-home initiation dosing for early Alzheimer's disease, with launch planned for late August 2026.

Media coverage

July 29 Fierce Pharma

Biogen flips '26 guidance from expected decline to sales increase

With increased sales of its newer drugs compensating for declining revenues from its multiple sclerosis (MS) portfolio, Biogen is once again positioned for a "growth...

July 29 BioSpace

Biogen shifts M&A strategy as Apellis acquisition pushes revenue above analyst expectations - BioSpace

Biogen officially began reporting revenue from the $5.6 billion acquisition of Apellis in the second quarter, shaking up analysts’ consensus estimates and leading to a...

July 29 Kalkine Media

Biogen Announces Q2 2026 Financial Results Highlighting Apellis Integration and Pipeline Progress

On July 29, 2026, Biogen released its financial and operational results for the second quarter of 2026 in a regulatory filing. The report details revenue...

July 29 Bloomberg

Biogen Beats Estimates as New Medicines Overtake MS Business

Biogen reported quarterly revenue and adjusted earnings that beat analysts’ expectations as sales of newly acquired kidney and eye-disease drugs helped offset declining revenue from multiple sclerosis medicines.

Never miss news about Biogen

Track Biogen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Biogen competitors & trending companies

Browse news for competitors to Biogen and other trending companies.